THERAPEUTIC FOCUS

GABA Therapeutics is developing GRX-917 for generalized anxiety disorder and evaluating a broad range of other neuropsychiatric and neurologic disorders.

GENERALIZED ANXIETY DISORDER

The primary mission for GABA Therapeutics is developing GRX-917 for GAD. GRX-917 will be clinically superior to America’s top two anxiety drug classes: SSRIs/SNRIs and benzodiazepines, and without sedation, cognitive impairment, withdrawal or abuse. Importantly, the existing, nondeuterated drug, is not classified as a controlled substance in any market where it is sold.

LEARN MORE

ADDITIONAL INDICATIONS

Preclinical and clinical studies indicate that GRX-917 could potentially benefit a broad range of neuropsychiatric and neurologic disorders that result from neurosteroids deficiency/dysregulation, as well as NLRP3 inflammation.

LEARN MORE